


# A COMBINED WORKFLOW FOR IN-DEPTH CHARACTERIZATION OF CYSTEINE-CONJUGATED ANTIBODY DRUG CONJUGATES

Liuxi Chen<sup>1</sup>, Robert Birdsall<sup>1</sup>, Henry Shion<sup>1</sup>, Ying Qing Yu<sup>1</sup>, Frank W. Kotch<sup>2</sup>, April Xu<sup>3</sup>, Thomas J. Porter<sup>4</sup>, Weibin Chen<sup>1</sup>

<sup>1</sup>Waters Corporation, Milford, MA; <sup>2</sup>Pfizer Bioprocess Research & Development, Pearl River, NY; <sup>3</sup>Pfizer Analytical Research & Development, Pearl River, NY; <sup>4</sup>Pfizer Analytical Research & Development, Andover, MA

## OVERVIEW



## INTRODUCTION




Fig. 1. Positional isoforms of cysteine-conjugated ADCs.

## METHODS

- HIC/UV, SEC-LC/MS, RP-LC/MS

### Instrumentation

LC: Waters ACQUITY H-Class Bio  
MS: Waters Xevo G2-S QToF

### Columns

Waters ProteinPak Hi Res HIC  
ACQUITY UPLC Protein BEH C4 Column, 300Å, 1.7 µm, 2.1 mm X 50 mm  
ACQUITY UPLC Protein BEH SEC Column, 200Å, 1.7 µm, 4.6 mm X 150 mm

- 2D LC/MS (HIC/RPLC)

### Instrumentation

LC: Waters ACQUITY H-Class Bio with 2D Technology  
MS: Xevo G2 QToF

### Columns

Waters Protein Pak Hi Res HIC  
ACQUITY UPLC Protein BEH C4, 300Å, 1.7 µm, 2.1 mm X 50 mm

- Peptide mapping


### Instrumentation

LC: Waters ACQUITY H-Class Bio  
MS: Xevo G2-XS QToF

### Columns

Waters ACQUITY UPLC CSH C18 Column, 130Å 1.7 µm, 2.1 mm X 100 mm

## Intact Analysis



	Drug loading distribution and DAR					
	Low		Mod		High	
	HIC	LC/MS	HIC	LC/MS	HIC	LC/MS
ADC 2	0.81	0.74	0.38	0.41	0.07	0.09
ADC 4	1.14	1.17	1.67	1.57	1.23	1.11
ADC 6	0.75	0.60	1.61	1.45	1.72	1.72
ADC 8	0.12	0.21	0.78	0.97	2.95	3.05
DAR	2.83	2.72	4.44	4.40	5.97	5.97

Table 1. DARs comparison between HIC and native SEC/LC-MS experiments, which shows excellent agreement between the two methods for all three drug loading levels.

Fig. 2. Cysteine-conjugated ADC analysis using HIC. Drug distribution was determined for three different samples with increasing drug load.

Fig. 3. Deconvoluted intact mass spectra for cysteine-conjugated ADCs from native SEC-LC/MS after deglycosylation.

## 2D-LC/MS (HIC/RPLC) - Positional Isomers Determination




Fig. 4. Heart-cut fractions of A) DAR 4, B) DAR 6a, and C) DAR 6c were performed from individual HIC separations of cysteine-conjugated ADCs. A reversed phase gradient of each cut produced up to 3 peaks representing subunits of the positional isomers. Deconvolution of each peak resulted in unambiguous identification of the isoform for each fraction.

## Subunit Analysis




Fig. 5. Total ion chromatogram of reverse phase separated subunits. The subunit structures for peaks 1-7 were shown above. Cys-ADCs samples were treated by FabULOUS and then reduced by DTT.

- Steric hindrance inhibits cleavage, resulting in 7=H\*\*\* (+3 drugs) peak.

## Peptide Mapping




Fig. 6. Tryptic peptide mapping MS<sup>E</sup> chromatogram of cys-conjugated ADC (Moderate). Heavy chain T21 peptides with two conjugation sites are shown as an example. Unconjugated T21 (1), T21 with 1 conjugation site (2 and 3), and T21 with 2 conjugation sites (4) are indicated on the chromatogram.

Chain	Pep#	Peptide sequence	Modifier	Drug Occupancy ratio
Light	1:T2	VTITCR	ADC_cys	7.3%
Light	1:T11	SGTASVYCLLNIFYPR	ADC_cys	1.2%
Light	1:T18	VYACVTHQGLSSPVTK	ADC_cys	2.1%
Light	1:T20	GEC	ADC_cys	100.0%
Heavy	2:T11	AEDTAVYYCAR	ADC_cys	1.9%
Heavy	2:T15	STSGGTAALGCLVK	ADC_cys	1.9%
Heavy	2:T20	SCDK	ADC_cys	100.0%
Heavy	2:T21	THTCPPCPAPEAAGAPSVLFPKPK	ADC_cys, CAM	5.9%
Heavy	2:T21	THTCPPCPAPEAAGAPSVLFPKPK	ADC_cys, CAM	4.8%
Heavy	2:T21	THTCPPCPAPEAAGAPSVLFPKPK	ADC_cys x2	24.6%
Heavy	2:T23	TPEVTCVVVDVSHEDPEVK	ADC_cys	1.5%
Heavy	2:T37	NQVSLTCLVK	ADC_cys	3.5%
Heavy	2:T42	WQQGNVFCFSVMHEALHNYTQK	ADC_cys	1.4%

Table 2. List of cys-conjugated peptides observed in the moderate loading sample. Drug occupancy ratio = MS intensity of conjugated/(MS intensity of unconjugated +conjugated peptides)

## CONCLUSION

- DAR values and drug loading distributions for cysteine-conjugated ADCs are automatically acquired from HIC-LC analysis and from native SEC-LC/MS analysis, and the results show excellent agreement.
- 2D-LC/MS provides unambiguous identification of positional isomers in cysteine-conjugated ADCs.
- LC/MS<sup>E</sup> identifies 13 conjugation sites with drug occupancy ratio calculated.

## References:

1. Details on the HIC-UV, SEC-LC/MS and RP-LC/MS analysis: 61st ASMS conference, poster number TP236
2. TP236 Details on 2D LC/MS analysis: 61st ASMS conference, poster number T2265

TO DOWNLOAD A COPY OF THIS POSTER, VISIT [WWW.WATERS.COM/POSTERS](http://WWW.WATERS.COM/POSTERS)